Table 2 Overall survival with clinicopathological findings
Variables | n = 79 (%) | 3-years OS rate (%) | 5-year OS rate (%) | Pvalue* | Â |
|---|---|---|---|---|---|
Age (years) | Â | Â | Â | Â | Â |
<60 | 27 (34.2) | 70.4 | 63.0 | 0.11 | Â |
≥60 | 52 (65.8) | 52.5 | 43.1 |  |  |
Gender | Â | Â | Â | Â | Â |
Male | 68 (86.1) | 58.9 | 50.8 | 0.91 | Â |
Female | 11 (13.9) | 57.7 | 46.2 | Â | Â |
Location | Â | Â | Â | Â | Â |
Upper | 12 (15.2) | 50.0 | 41.7 | control | Â |
Middle | 47 (59.5) | 61.0 | 48.2 | 0.76 | Â |
Lower | 20 (25.3) | 60.0 | 60.0 | 0.38 | Â |
cT | Â | Â | Â | Â | Â |
cT1 | 24 (30.4) | 85.9 | 76.4 | control | Â |
cT2 | 8 (10.1) | 85.7 | 71.4 | 0.94 | Â |
cT3 | 47 (59.5) | 41.5 | 34.4 | 0.0006 | Â |
cN | Â | Â | Â | Â | Â |
cN0 | 29 (36.7) | 80.8 | 72.7 | 0.0028 | Â |
cN1-3 | 50 (63.3) | 47.0 | 38.2 | Â | Â |
cStage | Â | Â | Â | Â | Â |
cStageI | 22 (27.8) | 89.5 | 79.0 | control | Â |
cStageII | 17 (21.5) | 67.0 | 60.3 | 0.25 | Â |
cStageIII | 40 (50.6) | 40.0 | 31.8 | 0.0002 | Â |
Clinical course | Â | Â | Â | Â | Â |
CR continue | 35 (44.3) | 87.5 | 84.1 | <0.0001 | Â |
Failure | 44 (55.7) | 37.3 | 25.5 | Â | Â |